Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$2.18 USD
-0.01 (-0.46%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $2.18 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SAVA 2.18 -0.01(-0.46%)
Will SAVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SAVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAVA
Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround
Is the Future Bleak for SAVA Stock Following Another Setback?
SAVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Other News for SAVA
Cassava Sciences (SAVA) Appoints New Chief Medical Officer
Cassava Sciences taps Joseph Hulihan as chief medical officer
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer | SAVA Stock News
Cassava Sciences appoints Hulihan as Chief Medical Officer
Cassava Sciences (SAVA) Reveals Positive Study Results for Epilepsy Treatment